Cover Image
市場調查報告書

原位雜合反應 (ISH)的全球市場預測 2021年:FISH、CISH、癌症診斷、細胞學、神經科學、免疫學、感染疾病

In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 338073
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
原位雜合反應 (ISH)的全球市場預測 2021年:FISH、CISH、癌症診斷、細胞學、神經科學、免疫學、感染疾病 In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021
出版日期: 2017年01月18日 內容資訊: 英文 194 Pages
簡介

全球原位雜合反應 (ISH) 市場規模預計從2016年的5億5,710萬美元到2021年達到7億3,990萬美元。

本報告提供全球原位雜合反應 (ISH) 市場相關調查,市場概要,市場的各種影響因素及市場機會分析,市場整體及各應用、終端用戶、地區的市場趨勢與市場成長預測,競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場概要

  • 促進要素
  • 抑制因素
  • 機會

第5章 各技術

  • FISH
    • DNA-FISH
    • RNA-FISH
  • CISH

第6章 各應用領域

  • 癌症診斷
  • 細胞學
  • 神經科學
  • 免疫學
  • 感染疾病

第7章 各終端用戶

  • 分子診斷實驗室
  • 大學 & 研究機關
  • CRO
  • 醫藥品 & 生物科技企業

第8章 地區分析

  • 北美
  • 歐洲
  • 亞洲
  • 其他 (RoW)

第9章 市場佔有率分析

  • ABBOTT (美國)
  • ROCHE DIAGNOSTICS (瑞士)
  • LEICA BIOSYSTEMS NUSSLOCH GMBH (德國)
  • AGILENT TECHNOLOGIES (美國)

第10章 競爭情形

  • 協定,合作,聯盟
  • 新產品銷售
  • 擴大
  • 收購
  • 其他

第11章 企業簡介

  • ABBOTT
  • ROCHE DIAGNOSTICS
  • LEICA BIOSYSTEMS NUSSLOCH GMBH
  • AGILENT TECHNOLOGIES

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 3649

"The in situ hybridization market is projected to reach USD 739.9 million by 2021 from USD 557.1 million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021)."

Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are some factors expected to drive the growth of the global in situ hybridization market in the coming years.

In 2016, North America is expected to account for the largest share of the global in situ hybridization market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents.

In the coming years, the in situ hybridization market is expected to witness the highest growth in the Asia-Pacific region, with emphasis on India, China, and Japan. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies [agreements, partnerships, collaborations, product launches, acquisitions, and expansions; and other strategies (including approvals, product enhancements, and product deployments] to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the adaptive security market place.

  • By Company Type: Tier 1: 50%, Tier 2: 42%, Tier 3: 8%
  • By Designation: Director Level: 58%, C-Level: 25%, Others: 17%
  • By Region: North America: 46%, Europe: 31%, APAC: 15%, ROW: 8%

The report includes the study of key players offering in situ hybridization technique such as Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.)

Research Coverage:

The focus of this report is on providing quantitative information for clients seeking market size information on various segments of the In Situ Hybridization market. It provides the current and forecast assessment of the Global In Situ Hybridization market. The report incorporates various segments such as by technique, application, end-user and regional analysis. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their market shares, company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the products and services offered by top players in the telehealth market. The report analyzes the in situ hybridization market by component, mode of delivery, and end user.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the in situ hybridization market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for in situ hybridization across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the in situ hybridization market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the in situ hybridization market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
    • 2.2.3. KEY INDUSTRY INSIGHTS
  • 2.3. KEY DATA FROM PRIMARY SOURCES
  • 2.4. KEY INSIGHTS FROM PRIMARY SOURCES
  • 2.5. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.5.1. RESEARCH DESIGN
  • 2.6. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

  • 4.1. INTRODUCTION
  • 4.2. MARKET DYNAMICS
    • 4.2.1. DRIVERS
    • 4.2.2. RESTAINTS/CHALLENGES
    • 4.2.3. OPPORTUNITIES

5. IN SITU HYBRIDIZATION MARKET, BY TECHNIQUE

  • 5.1. INTRODUCTION
  • 5.2. FLUORESCENCE IN SITU HYBRIDIZATION MARKET (FISH)
    • 5.2.1. DNA-FISH
    • 5.2.2. RNA-FISH
  • 5.3. CHROMOGENIC IN SITU HYBRIDIZATION MARKET (CISH)

6. IN SITU HYBRIDIZATION MARKET, BY APPLICATION

  • 6.1. INTRODUCTION
  • 6.2. CANCER DIAGNOSIS
  • 6.3. IMMUNOLOGY
  • 6.4. NEUROSCIENCE
  • 6.5. CYTOLOGY
  • 6.6. INFECTIOUS DISEASES

7. IN SITU HYBRIDIZATION MARKET, BY END-USER

  • 7.1. INTRODUCTION
  • 7.2. MOLECULAR DIAGNOSTIC LABORATORIES
  • 7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 7.4. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 7.5. ACADEMIC & RESEARCH INSTITUTIONS

8. IN SITU HYBRIDIZATION MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. U.S.
    • 8.2.2. CANADA
  • 8.3. EUROPE
    • 8.3.1. EU5- (U.K, GERMANY, FRANCE, SPAIN & ITALY)
    • 8.3.2. REST OF EUROPE (ROE)
  • 8.4. ASIA-PACIFIC
  • 8.5. REST OF THE WORLD

(Consolidated Market Numbers for Latin America, Middle-East and Africa Will Be Provided)

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. COMPETITIVE SITUATION AND TRENDS
    • 9.2.1. APPROVALS
    • 9.2.2. PRODUCT DEPLOYMENTS
    • 9.2.3. NEW PRODUCT LAUNCHES
    • 9.2.4. OTHERS (IF ANY)

10. COMPANY PROFILES#

  • 10.1. INTRODUCTION
  • 10.2. ABBOTT LABORATORIES, INC.
    • 10.2.1. BUSINESS OVERVIEW
    • 10.2.2. FINANCIAL OVERVIEW
    • 10.2.3. PRODUCT OFFERINGS
    • 10.2.4. RECENT DEVELOPMENTS
  • 10.3. F.HOFFMANN-LA ROCHE LTD.
  • 10.4. THERMOFISHER SCIENTIFIC, INC.
  • 10.5. MERCK KGAA
  • 10.6. AGILENT TECHNOLOGIES, INC.
  • 10.7. PERKIN ELMER, INC.
  • 10.8. DANAHER CORPORATION / LEICA BIOSYSTEMS NUSSLOCH GMBH
  • 10.9. EXIQON A/S
  • 10.10. BIOGENEX LABORATORIES, INC.
  • 10.11. ADVANCED CELL DIAGNOSTICS, INC
  • 10.12. BIO SB, INC.

LIST OF TABLES

  • TABLE 1: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION/COUNTRY, 2016 (USD MILLION)
  • TABLE 2: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 3: GLOBAL FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: NORTH AMERICA: FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 5: EUROPE: FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 6: GLOBAL DNA-FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: NORTH AMERICA: DNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 8: EUROPE: DNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 9: GLOBAL RNA-FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: NORTH AMERICA: RNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 11: EUROPE: RNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 12: GLOBAL CISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: NORTH AMERICA: CISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 14: EUROPE: CISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 16: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CANCER DIAGNOSIS, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 17: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CYTOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 18: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR NEUROSCIENCE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 19: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR IMMUNOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 20: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 21: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 22: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 27: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 30: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 33: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 37: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 38: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 40: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 41: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 42: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 43: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 44: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 48: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 49: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 50: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 51: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 53: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 54: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 56: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 57: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 59: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 60: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: MARKET SIZE ESTIMATION - USD VALUE
  • FIGURE 2: MARKET SIZING - (USD VALUE ANALYSIS)
  • FIGURE 3: COMPETITIVE ASSESSMENT
  • FIGURE 4: RESEARCH DESIGN
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: GLOBAL IN SITU HYBRIDIZATION MARKET, BY TECHNIQUE, 2016 (USD MILLION)
  • FIGURE 7: GLOBAL IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2016 (USD MILLION)
  • FIGURE 8: GLOBAL IN SITU HYBRIDIZATION MARKET, BY END USER, 2016 (USD MILLION)
  • FIGURE 9: MARKET OVERVIEW
  • FIGURE 10: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY TECHNIQUE
  • FIGURE 11: THE FISH TECHNIQUE SEGMENT IS EXPECTED TO DOMINATE THE IN SITU HYBRIDIZATION MARKET IN 2016
  • FIGURE 12: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 13: CANCER DIAGNOSIS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: TIMELINE OF FDA APPROVALS FOR KEY FISH-BASED COMPANION DIAGNOSTICS IN ONCOLOGY
  • FIGURE 15: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY END USER
  • FIGURE 16: MOLECULAR DIAGNOSTIC LABORATORIES DOMINATE THE IN SITU HYBRIDIZATION MARKET, BY END USER (2016)
  • FIGURE 17: MARKET SHARE ANALYSIS
  • FIGURE 18: SHARE OF KEY STRATEGIES (2013-2016)
  • FIGURE 19: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS (2013-2016)
  • FIGURE 20: PRODUCT LAUNCHES (2013-2016)
  • FIGURE 21: EXPANSIONS (2013-2016)
  • FIGURE 22: ACQUISITIONS (2013-2016)
  • FIGURE 23: OTHER STRATEGIES (2013-2016)
  • FIGURE 24: ROUTE TO GROWTH: ORGANIC VS. INORGANIC STRATEGIES
  • FIGURE 25: ORGANIC GROWTH STRATEGIES
  • FIGURE 26: INORGANIC GROWTH STRATEGIES
Back to Top